



٠



MFI Granz.B on CD 8+ T cells

• -

2000

*

1000

ğ



Β



pg CCL4/mg tumor













Garate-Soraluze E, et al. J Immunother Cancer 2025; 13:e009852. doi: 10.1136/jitc-2024-009852

8











300

400













CCL4





...





6000

Granzyme

ω











pg IFNy/mg tumor

ē 0

•



C

Sample Type

SampleType Vehicle RT

muFAP-4-1-BBL RT+muFAP-4-1-BBL

Cav. Tgfb3

ion

Expr











Supplemental Figure 5. Combination of radiotherapy and muFAP-4-1BBL results in upregulation of CD8⁺ T cells' effector phenotype markers and proinflammatory chemokines. The primary tumor of TS/A+CAFs tumor bearing mice were treated with hypofractionated radiotherapy (RT, day 8 and 9) whereas the contralateral tumor was not irradiated. For combination treatment mice received additional peritoneal injection of muFAP-4-1BBL (day 9). (A) At day 15 tumors were harvested for flow cytometry analysis. Plots of median fluorescence intensity (MFI) showing Granzyme B and Ki67 expression on CD8⁺ T cells on primary (irradiated) and contralateral tumors (non-irradiated) upon previous 4 hours re-stimulation with PMA/Ionomycin are shown as mean \pm SEM; each symbol represents one mouse (n=5 mice/group) (t-test one-tailed). (B) Plots presenting the indicated chemokines measured by Luminex xMAP Technology in primary tumors of indicated mice groups at day 15 (n=6 mice/group). Each symbol represents one mouse, means \pm SEM are indicated (t-test one-tailed), **p* < .05, ***p* < .01, ****p* < .001. (C) Heatmap of listed genes analyzed by RNAseq of the tumor at day 11. Three mice of each treatment group were analyzed as indicated.